Core Viewpoint - Precision Optics Corporation has announced the pricing of its public offering of 2,777,777 shares at $3.60 per share, indicating strong interest from both existing and new institutional investors [1][2]. Group 1: Offering Details - The offering was oversubscribed and included participation from company executives, such as the President and CEO, who purchased shares at the public offering price [2]. - Lucid Capital Markets is the sole book-running manager for the offering, which is expected to close on or about March 30, 2026, subject to customary closing conditions [3]. - The company has granted the underwriter a 45-day option to purchase an additional 416,667 shares at the public offering price [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for working capital and general corporate purposes [4]. Group 3: Company Overview - Precision Optics Corporation, founded in 1982, specializes in advanced optical instruments for the medical and defense/aerospace industries, leveraging proprietary technologies [7]. - The company provides services from product concept to mass manufacture, focusing on next-generation medical devices and defense applications [7].

Company Overview - Precision Optics Corporation, Inc. is a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, founded in 1982 [5] - The company focuses on leveraging proprietary micro-optics, 3D imaging, and digital imaging technologies to meet the demands of healthcare and defense/aerospace sectors [5] - Precision Optics provides services ranging from new product concept through mass manufacture, utilizing in-house design, prototype, regulatory, and fabrication capabilities [5] Public Offering Announcement - Precision Optics Corporation has announced the commencement of an underwritten public offering of shares of its common stock, subject to market conditions [1] - Lucid Capital Markets is acting as the sole book-running manager for the offering, which is made pursuant to a shelf registration statement filed with the SEC [2] - A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC and made available on the SEC's website [3]

Core Viewpoint - Cibus, Inc. has announced a public offering of 6,976,744 shares of its Class A Common Stock at a price of $2.15 per share, aiming to raise approximately $15 million for working capital and corporate purposes, particularly for the development of weed management traits in rice [1][3]. Group 1: Offering Details - The offering includes a 30-day option for the underwriter to purchase an additional 1,046,511 shares to cover over-allotments [2]. - The gross proceeds from the offering are expected to be around $15 million, or $17.2 million if the underwriter fully exercises its option [3]. - The offering is set to close on March 27, 2026, pending customary closing conditions [3]. Group 2: Company Overview - Cibus is a leading agricultural technology company focused on developing and licensing plant traits to seed companies, utilizing high-throughput gene editing technologies [7]. - The company is not a seed company but a technology firm that aims to enhance productivity traits for major global row crops at a lower cost and time compared to conventional breeding methods [7].

Company Overview - Unusual Machines, Inc. is a U.S.-based manufacturer and distributor of drone parts, aiming to be a dominant Tier-1 parts supplier in the rapidly growing multi-billion-dollar U.S. drone industry [6] - The company has a diversified brand portfolio, including Fat Shark, known for ultra-low latency video goggles for drone pilots, and retails FPV drones and equipment through the Rotor Riot ecommerce store [6] Proposed Public Offering - Unusual Machines has announced a public offering of Common Stock to expand its U.S. drone parts inventory and for working capital and general corporate purposes [1] - The offering is subject to market conditions, and there is no assurance regarding its completion or the actual size and terms [1] Market Context - The global drone accessories market is currently valued at $17.5 billion and is projected to exceed $115 billion by 2032, indicating significant growth potential for companies in this sector [6]

Core Viewpoint - SAB Biotherapeutics, Inc. has announced a public offering of common stock and pre-funded warrants to raise approximately $85 million to fund the development of its clinical-stage product candidate, SAB-142, targeting type 1 diabetes and other autoimmune diseases [1][2]. Group 1: Offering Details - The company is offering 19,324,677 shares of common stock at a price of $3.85 per share and pre-funded warrants for 2,753,246 shares at $3.8499 each, with gross proceeds expected to be around $85 million before expenses [1]. - Underwriters have a 30-day option to purchase an additional 3,311,688 shares on the same terms [1]. - The offering is expected to close on or about March 19, 2026, pending customary closing conditions [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to fund the continued development of SAB-142 through clinical trials, manufacturing, regulatory activities, and general corporate purposes [2]. Group 3: Company Overview - SAB Biotherapeutics is focused on developing human immunoglobulin G (hIgG) to treat autoimmune disorders, utilizing advanced genetic engineering and proprietary technology [6]. - The lead candidate, SAB-142, aims to modify the treatment paradigm for type 1 diabetes by delaying onset and potentially preventing disease progression in Stage 3 patients [6]. - SAB-142 is currently in a registrational Phase 2b clinical trial named SAFEGUARD [6].

Core Viewpoint - Optimi Health Corp. has initiated an underwritten public offering of its common shares in the United States as part of its strategy to list on the Nasdaq Capital Market [1][2] Group 1: Offering Details - The offering will be managed by Joseph Gunnar & Co., LLC, and the company has applied to list its shares on Nasdaq under the symbol "OPTH" [2] - The offering is subject to market conditions and the completion of the SEC and Nasdaq review process, with no assurance on the timing or terms of completion [4][16] - The offering will be conducted under a prospectus as part of an effective registration statement filed with the SEC [3] Group 2: Share Consolidation - The company's board has approved a consolidation of its outstanding shares at a ratio of one post-consolidation share for every thirty pre-consolidation shares [7] - This consolidation aims to meet Nasdaq's minimum share price requirement and will not affect shareholders' proportionate ownership, except for fractional shares [8][9] - Following the consolidation, the company expects to have approximately 3,225,897 shares outstanding [9] Group 3: Company Overview - Optimi Health Corp. is a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies [12] - The company produces validated MDMA and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia, Canada [12] - Optimi supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally [13]

Group 1 - Palvella Therapeutics, Inc. announced the pricing of its upsized public offering of 1,600,000 shares at $125.00 per share, with expected gross proceeds of $200 million [1] - The offering includes a 30-day option for underwriters to purchase an additional 240,000 shares [1] - The offering is expected to close on or about February 27, 2026, subject to customary closing conditions [1] Group 2 - The net proceeds from the offering will be used to support the development of programs including QTORIN rapamycin and QTORIN pitavastatin, as well as for working capital and general corporate purposes [3] - The offering is made pursuant to a shelf registration statement declared effective by the SEC on January 29, 2026 [4] Group 3 - Palvella is focused on developing therapies for serious, rare skin diseases and vascular malformations, with a pipeline based on its patented QTORIN™ platform [6] - The lead product candidate, QTORIN™ rapamycin, is being developed for microcystic lymphatic malformations and other conditions, while QTORIN™ pitavastatin is for the treatment of disseminated superficial actinic porokeratosis [6][7]

Core Viewpoint - Select Water Solutions, Inc. has announced a public offering of $175.0 million of its Class A common stock to support general corporate purposes, including water infrastructure growth, potential acquisitions, and debt repayment [1] Group 1: Offering Details - The public offering is for $175.0 million of Class A common stock, with a par value of $0.01 per share [1] - The company plans to grant underwriters a 30-day option to purchase up to $26.25 million of additional shares at the public offering price [1] - J.P. Morgan Securities LLC and BofA Securities are the lead book-running managers for the offering [1] Group 2: Use of Proceeds - Net proceeds from the offering will be used for general corporate purposes, including water infrastructure growth capital projects, potential acquisitions, or debt repayment under the sustainability-linked credit facility [1] Group 3: Regulatory and Market Conditions - The offering is subject to market and other conditions, with no assurance on the completion or terms of the offering [1] - The offering is being conducted under an effective shelf registration statement filed with the SEC [1]

Core Viewpoint - Genesis Energy, L.P. has successfully priced a public offering of $750 million in senior notes, up from the previously announced $500 million, with a fixed interest rate of 6.75% due in 2034 [1] Group 1: Offering Details - The public offering consists of $750 million in aggregate principal amount of senior notes, which will be co-issued with Genesis Energy Finance Corporation and guaranteed by all subsidiaries except unrestricted ones [1] - The notes will be sold at 100% of their principal amount, and the offering is expected to settle on March 4, 2026, pending customary closing conditions [1] Group 2: Use of Proceeds - The net proceeds from the offering will be used to purchase or redeem all outstanding 7.75% senior notes due 2028 and for general partnership purposes, including repaying a portion of revolving borrowings under the senior secured credit facility [1] Group 3: Market Participation - BofA Securities and Citigroup are acting as joint global coordinators for the offering, with several other financial institutions serving as joint book-running managers [1]

Core Viewpoint - Baltic Horizon Capital AS is offering up to 169,147,497 new units of Baltic Horizon Fund to existing investors, with proceeds aimed at deleveraging the fund's portfolio and enhancing assets [1]. Offering Details - The offering is exclusively for existing investors, with a public offering arranged in Estonia and available to investors in other European Economic Area jurisdictions under specific exemptions [3]. - The offer period starts at 10:00 on 23 February 2026 and ends at 16:00 on 3 March 2026, with the possibility of extension by the company [4]. - The offer price per unit is set at EUR 0.1478, and subscriptions can only be made for whole units [6]. Subscription Process - Existing investors can subscribe for units based on their holdings as of 20 February 2026, multiplied by a coefficient of 1.1782, allowing for a maximum subscription of 1178 units for every 1000 units held [7]. - Investors must hold a securities account in the Estonian Register of Securities and authorize the blocking of the transaction amount until the offering is settled [8]. - A detailed subscription order form is required, specifying the investor's details and the number of units they wish to subscribe for [12]. Key Dates - Key dates for the offering include: - 23 February 2026: Commencement of the offer period - 3 March 2026: End of the offer period - On or about 4 March 2026: Announcement of allocation results - On or about 9 March 2026: Delivery of allocated units and start of trading on Nasdaq Tallinn [11].